Choices in IgG replacement therapy for primary immune deficiency diseases
- 1 December 2011
- journal article
- review article
- Published by Ovid Technologies (Wolters Kluwer Health) in Current Opinion in Allergy and Clinical Immunology
- Vol. 11 (6), 532-538
- https://doi.org/10.1097/aci.0b013e32834c22da
Abstract
Subcutaneous IgG (SCIG) is becoming more popular, but there is still uncertainty about efficacy and optimal dosing. This review discusses recent pharmacokinetic studies and applications of SCIG therapy, and its efficacy in the context of emerging understanding of the relationship between dosing and efficacy of both intravenous IgG (IVIG) and SCIG replacement therapy for primary immunodeficiency diseases. Three preparations of IgG have been licensed in the US in the past year. Their bioavailabilities are 65-70% of that of IVIG. Pooled analyses show that the efficacy of SCIG in preventing infections is proportional to the steady-state levels achieved, and similar to that of IVIG. Pharmacokinetic studies allow estimation of doses that will yield desired serum levels with both IVIG and SCIG, and when switching from one route to another. Pooled analyses show that at equivalent total doses, weekly SCIG results in steady-state levels 10-20% higher than troughs on monthly IVIG. For most patients, the choice between routes should be based on individual preference, and the regimen should be individualized to achieve the desired outcomes.Keywords
This publication has 27 references indexed in Scilit:
- Efficacy, Safety, and Pharmacokinetics of a 10% Liquid Immune Globulin Preparation (GAMMAGARD LIQUID, 10%) Administered Subcutaneously in Subjects with Primary Immunodeficiency DiseaseJournal of Clinical Immunology, 2011
- The Construction of a Pharmacokinetic Model to Describe Intravenous and Subcutaneous Supplementation of IgG in Patients with Primary Immunodeficiency (PID)Journal of Allergy and Clinical Immunology, 2011
- Pharmacokinetics of subcutaneous immunoglobulin and their use in dosing of replacement therapy in patients with primary immunodeficienciesClinical Immunology, 2011
- History of Immunoglobulin ReplacementImmunology and Allergy Clinics of North America, 2008
- Subcutaneous Administration of IgGImmunology and Allergy Clinics of North America, 2008
- Pharmacokinetics of Immunoglobulin Administered via Intravenous or Subcutaneous RoutesImmunology and Allergy Clinics of North America, 2008
- Safety and Efficacy of Self-Administered Subcutaneous Immunoglobulin in Patients with Primary Immunodeficiency DiseasesJournal of Clinical Immunology, 2006
- A history of immune globulin therapy, from the harvard crash program to monoclonal antibodiesCurrent Allergy and Asthma Reports, 2002
- Slow subcutaneous immunoglobulin therapy in a patient with reactions to intramuscular immunoglobulinJournal of Clinical Immunology, 1983
- Immunoglobulin Replacement Therapy by Slow Subcutaneous InfusionAnnals of Internal Medicine, 1980